PR Newswire
NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. (“Ventyx”) (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.
If you have information that could assist in the Ventyx Investigation or if you are a Ventyx investor who suffered a loss and would like to learn more, you can provide your information
HERE
.
You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at [email protected].
THE COMPANY:
Ventyx Biosciences develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases.
THE ALLEGED WRONGDOING:
On December 2, 2025, Ventyx updated its Phase 2 trial of VTX2735 for recurrent pericarditis, announcing that topline results are now expected in Q1 2026. The CEO explained that the delay will allow the company to test a new once-daily formulation and expand the study into Canada, the EU, and the UK to accelerate Phase 3 development. On this news, Ventyx’s stock price fell $1.44 per share, or 15.35%, to close at $7.94 per share on December 2, 2025.
ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.
For more information, please contact:
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 ext. 1
Email: [email protected]
Web: www.edelson-law.com
This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-302656991.html
SOURCE Edelson Lechtzin LLP
